Evidence map›Paper›PMID 32817274›Full record

ReviewPharmacological reviews2020

Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies.

Catherine A Christian, Doodipala Samba Reddy, Jamie Maguire, Patrick A Forcelli

Open access · bronzeAbstract readReview
In one paragraph

Review in Pharmacological reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Holistic management of epilepsy in adults with intellectual development disorders.Epileptic disorders : international epilepsy journal with videotape · 2026
    Article
  6. Circadian Rhythms Time Seizure Severity inJournal of biological rhythms · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Modulation ofCurrent neuropharmacology · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Catherine A ChristianDepartment of Molecular and Integrative Physiology, Neuroscience Program, and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois (C.A.C.); Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M University Health Science Center, Bryan, Texas (D.S.R.); Neuroscience Department, Tufts University School of Medicine, Boston, Massachusetts (J.M.); and Departments of Pharmacology and Physiology and Neuroscience, Georgetown University, Washington, D.C. (P.A.F.) cathchri@illinois.edu.
Doodipala Samba ReddyDepartment of Molecular and Integrative Physiology, Neuroscience Program, and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois (C.A.C.); Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M University Health Science Center, Bryan, Texas (D.S.R.); Neuroscience Department, Tufts University School of Medicine, Boston, Massachusetts (J.M.); and Departments of Pharmacology and Physiology and Neuroscience, Georgetown University, Washington, D.C. (P.A.F.).
Jamie MaguireDepartment of Molecular and Integrative Physiology, Neuroscience Program, and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois (C.A.C.); Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M University Health Science Center, Bryan, Texas (D.S.R.); Neuroscience Department, Tufts University School of Medicine, Boston, Massachusetts (J.M.); and Departments of Pharmacology and Physiology and Neuroscience, Georgetown University, Washington, D.C. (P.A.F.).
Patrick A ForcelliDepartment of Molecular and Integrative Physiology, Neuroscience Program, and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois (C.A.C.); Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M University Health Science Center, Bryan, Texas (D.S.R.); Neuroscience Department, Tufts University School of Medicine, Boston, Massachusetts (J.M.); and Departments of Pharmacology and Physiology and Neuroscience, Georgetown University, Washington, D.C. (P.A.F.).
Texas A&M University · USGeorgetown University · USTexas A&M Health Science Center · US

Funding

Investigating the pathological consequences of seizure-induced activation of the HPA axisR01NS102937 · NINDS · TUFTS UNIVERSITY BOSTON · PI Jamie Lynn Maguire · 2017 to 2026
$4.2M
Optogenetic control of seizures via the basal gangliaR01NS097762 · NINDS · GEORGETOWN UNIVERSITY · PI Patrick Alexander Forcelli · 2016 to 2026
$4.1M
Neurosteroid Treatment for OP IntoxicationU01NS083460 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2013 to 2017
$3.4M
Structural and functional sequelae of neonatal anticonvulsant exposure: drug-seizure interactionsR01HD091994 · NICHD · GEORGETOWN UNIVERSITY · PI FORCELLI, PATRICK ALEXANDER · 2018 to 2022
$2.9M
Neural and pituitary mechanisms linking epilepsy to co-morbid reproductive endocrine dysfunctionR01NS105825 · NINDS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI CHRISTIAN-HINMAN, CATHERINE A · 2018 to 2022
$1.8M
Disruption in the network communication of safety in epilepsy with comorbid anxietyR01NS105628 · NINDS · TUFTS UNIVERSITY BOSTON · PI MAGUIRE, JAMIE LYNN · 2019 to 2022
$1.6M
Progesterone Receptors and Seizure SusceptibilityR01NS051398 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2007 to 2011
$1.5M
Neuroactive Steroid Therapy of Catamenial EpilepsyR21NS052158 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2006 to 2007
$324k
Lateralized targeting of hippocampus to model interactions between epilepsy and reproductive endocrine disordersR03NS103029 · NINDS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI CHRISTIAN-HINMAN, CATHERINE A · 2018 to 2019
$199k
NICHD NIH HHS R01 HD091994NINDS NIH HHS R01 NS051398NINDS NIH HHS R01 NS097762NINDS NIH HHS R01 NS102937NINDS NIH HHS R01 NS105628NINDS NIH HHS R01 NS105825NINDS NIH HHS R03 NS103029NINDS NIH HHS R21 NS052158NINDS NIH HHS U01 NS083460
6 · The paper itself

Abstract

The epilepsies are common neurologic disorders characterized by spontaneous recurrent seizures. Boys, girls, men, and women of all ages are affected by epilepsy and, in many cases, by associated comorbidities as well. The primary courses of treatment are pharmacological, dietary, and/or surgical, depending on several factors, including the areas of the brain affected and the severity of the epilepsy. There is a growing appreciation that sex differences in underlying brain function and in the neurobiology of epilepsy are important factors that should be accounted for in the design and development of new therapies. In this review, we discuss the current knowledge on sex differences in epilepsy and associated comorbidities, with emphasis on those aspects most informative for the development of new pharmacotherapies. Particular focus is placed on sex differences in the prevalence and presentation of various focal and generalized epilepsies; psychiatric, cognitive, and physiologic comorbidities; catamenial epilepsy in women; sex differences in brain development; the neural actions of sex and stress hormones and their metabolites; and cellular mechanisms, including brain-derived neurotrophic factor signaling and neuronal-glial interactions. Further attention placed on potential sex differences in epilepsies, comorbidities, and drug effects will enhance therapeutic options and efficacy for all patients with epilepsy. SIGNIFICANCE STATEMENT: Epilepsy is a common neurological disorder that often presents together with various comorbidities. The features of epilepsy and seizure activity as well as comorbid afflictions can vary between men and women. In this review, we discuss sex differences in types of epilepsies, associated comorbidities, pathophysiological mechanisms, and antiepileptic drug efficacy in both clinical patient populations and preclinical animal models.

Indexed as

AnimalsAnticonvulsantsComorbidityDisease Models, AnimalEpilepsyFemaleHumansMaleRandomized Controlled Trials as TopicSex FactorsAnticonvulsants

Identifiers

PMID32817274
PMCPMC7495340
OpenAlexW3074825168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.